Clinical trial
Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the…
NCT00211523 · BioWest Therapeutics Inc, Industry · Completed
Key facts
| NCT number | NCT00211523 |
|---|---|
| Title | Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne |
| Official title | Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of MBI 226 2.5% and 5.0% Acne Solutions Applied Topically for 6 Weeks to Subjects With Acne Vulgaris |
| Lead sponsor | BioWest Therapeutics Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acne Vulgaris, Acne, Propionibacterium Acnes |
| Intervention type | Drug |
| Interventions | MBI 226 Acne Solutions |
| Enrollment | 75 |
| Start date | Oct 1, 2000 |
| Completion | Sep 1, 2001 |
| First posted | Sep 21, 2005 |
| Last update posted | Sep 21, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: